Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibodies Response After Its Single Dose of Reduced-antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Tdap) in Thai Pregnant Women

Trial Profile

Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibodies Response After Its Single Dose of Reduced-antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Tdap) in Thai Pregnant Women

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs DTaP vaccine (Primary)
  • Indications Diphtheria; Pertussis; Tetanus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 06 Oct 2018 Planned End Date changed from 1 Feb 2019 to 1 Apr 2019.
    • 06 Oct 2018 Status changed from not yet recruiting to active, no longer recruiting.
    • 17 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top